Two-Part, Open-Label Study to Evaluate Single Dose Pharmacokinetics of an Obefazimod Minitablet Formulation, Estimate the Relative Bioavailability of the Minitablet Formulation and to Evaluate Minitablet Palatability in Healthy Participants
Latest Information Update: 13 Apr 2026
At a glance
- Drugs Obefazimod (Primary)
- Indications COVID 2019 infections; Crohn's disease; Inflammatory bowel diseases; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Abivax
Most Recent Events
- 06 Apr 2026 Status changed from not yet recruiting to recruiting.
- 10 Mar 2026 New trial record